Rangering i aksjer
#36618
Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy,... Lysogene S.A. is a biopharmaceutical firm specializing in gene therapy, dedicated to discovering and advancing treatments for children affected by severe neurodegenerative lysosomal storage disorders. Its development pipeline includes LYS-SAF302, which is currently undergoing Phase II/III clinical trials for mucopolysaccharidosis type IIIA (MPS IIIA). Another promising candidate, LYS-GM101, is in Phase I/II development, targeting GM1 gangliosidosis. The company has also forged a research alliance with the Weizmann Institute of Science to pioneer novel adeno-associated virus (AAV) gene therapy approaches for conditions such as neuronopathic Gaucher disease, Parkinson's disease, and other related illnesses. Lysogene S.A. was established in 2009 and is headquartered in Neuilly-sur-Seine, France.
Aksjekurs
$0.30221445
Sist synkronisert: 2023-05-22
Handel Lysogene S.A. (LYS)
Pris LYS pris med markedsverdi på B
Markedsverdi av Lysogene S.A.(LYS)
Markedsverdi: $2.49M
Per August 2026 har Lysogene S.A. en markedsverdi på $2.49M. Dette gjør Lysogene S.A. til det 36618th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Lysogene S.A. fra 2017 til 2026
LYS sammenlignet med topp 5 mest populære stocks
| Pris på LYS |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.452T
|
+218,595,217.06%
|
|
|
|
|
$4.490T
|
+180,029,466.10%
|
|
|
|
|
$4.162T
|
+166,893,655.77%
|
|
|
|
|
$3.676T
|
+147,404,657.49%
|
|
|
|
|
$2.833T
|
+113,592,136.88%
|
